Current Atherosclerosis Reports

, Volume 10, Issue 1, pp 71–78

Rimonabant: New data and emerging experience

  • Suzanne M. Wright
  • Carolien Dikkers
  • Louis J. Aronne
Article

DOI: 10.1007/s11883-008-0011-5

Cite this article as:
Wright, S.M., Dikkers, C. & Aronne, L.J. Curr Atheroscler Rep (2008) 10: 71. doi:10.1007/s11883-008-0011-5

Abstract

The endogenous cannabinoid system has been identified as playing a central role in the regulation of energy homeostasis, and its overactivity has been associated with obesity. Rimonabant is a selective endocannabinoid CB1 receptor antagonist that has been shown to be an effective treatment for obesity and cardiometabolic risk factors. Studies comparing 20 mg/d of rimonabant with placebo show a placebo-subtracted weight loss between 6.3 and 6.9 kg at 1 year. In addition to the health benefits already associated with weight loss, rimonabant has shown additional improvements in lipid and glycemic cardiometabolic biomarkers such as low-density lipoprotein cholesterol, triglycerides, C-reactive protein, glucose, and adiponectin. The use of endo-cannabinoid antagonists such as rimonabant provides a promising therapeutic approach to the treatment of obesity and its associated cardiometabolic risks.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Suzanne M. Wright
    • 1
  • Carolien Dikkers
  • Louis J. Aronne
  1. 1.Comprehensive Weight Control Program, New York-Presbyterian HospitalWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations